There are different types of psychedelics some natural, others artificially made in laboratories. The natural ones occur in trees, plant fungi, vines, and leaves. Each of these substances works differently on the body. Overall, psychedelics are being used in clinical trials to determine the effect of these substances, and their medicinal value, if any.
Over the years across the globe, various cultures have been using psychedelics for their spiritual and mystical associations. They are commonly used to treat mental disorders and are known to have emotional, physiological, and psychological effects.
Even though there have been some promising results, recent studies show that doctors need to be more cautious when using these psychedelic substances for treatment.
Jeremy Weate, an experienced ibogaine facilitator narrates the dangers involved as observed in trials he’s been a part of. For starters, Ibogaine is a psychoactive substance used for ritual and medicinal purposes in some parts of Africa. It slowly gained popularity in Europe and other parts of the world for its anti-addictive properties. Many researchers have picked up on iboga in an attempt to identify its health benefits.
In a guest post, Jeremy details confessions about key things they observed about the drug while handling patients with addiction problems. Jeremy Weate, together with Alvaro de Ferranti (a recovered cocaine addict) had initially opened an iboga retreat center in Portugal. The mission of their full-fledged clinic was to provide these treatments in a “holistic setting with a focus of pre- and aftercare, avoiding the drive-thru ibogaine that is all too often found elsewhere.”
They hired holistic therapists, counselors, a fitness coach, and a safety outfit for their ibogaine clinic. Part of the treatments in their program includes equine therapy, massage, meditation, yoga, breathwork, vocal toning, sound therapy, and light therapy.
After a few trials, they faced a number of challenges especially when it came to getting the right dosage. Here’s a look at some of the challenges they faced, lessons learned, and advice on the importance of taking precautions when treating patients using psychedelic substances, specifically, ibogaine.
Safety should be a priority
He reinforces the need to get the proper dosage and advocates for conservative dosing.
Be prepared for any emergency
Anything can go wrong. Imagine a patient suffering from a heart attack and not having an emergency team to immediately help take care of the situation.
Not everyone can take flood doses
Most bodies cannot withstand a heavy dosage of ibogaine and that he brain doesn’t need all that amount for it to reset. Secondly, other factors influence the mg/kg dosage because bodies metabolize ibogaine differently. For instance, if the person used drugs previously, the body will react differently depending on the dosage.
For best results, ibogaine should not be used in isolation
Even though it shows promising results in helping interrupt addiction, it is just one of the tools and thus preaching ibogaine evangelism is a mistake.
Must consider Aftercare
Mentorship and therapy are critical conventional treatments that ibogaine cannot replace, and therefore should be incorporated in the program.
It’s important to do pre-treatment therapy
The patient has to be psychologically ready to take the treatment.
Holistic treatments used together with conventional addiction counseling provide the best results.
Ibogaine facilitators urge other researchers and clinicians to be open about discussing the possible adverse effects of psychedelic treatments and the importance of taking precautions.
This list of recommendations could explain why sector players like Field Trip Psychedelics Inc. advocate for the use of psychedelics in clinical settings where all the precautions above can be taken.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.